PTPRC and myelodysplastic syndrome: In SRSF2 mutant MDS, a distinct immunophenotype was identified by Weiß et al., exhibiting a specific CD11b/CD16 co-expression pattern in granulocytes and reduced CD45 expression in myeloid progenitors.